Nd:YAG vs Alexandrite Laser Treatment in Hidradenitis Suppurativa

Geisinger Health

Status: Begins enrollment in 1 month

Conditions: Hidradenitis Suppurativa (HS)

Treatments: Device: Alexandrite Laser; Device: Nd:YAG Laser

Study type: Interventional

Funder types: Other

Identifiers

NCT06960447

2024-0947

Details and patient eligibility

About

The purpose of this study is to evaluate whether Alexandrite laser treatment is non-inferior to Nd:YAG (neodymium-doped yttrium aluminum garnet) laser treatment of hidradenitis suppurativa (HS).

Enrollment: 21 estimated patients

Sex: All

Ages: 12 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Geisinger male or female patients with a diagnosis of hidradenitis suppurativa (all stages of disease)
• 12-75 years of age
• Not on concurrent systemic therapy (e.g., antibiotics, biologic therapies)
• Must have not used systemic therapies within 2 weeks of enrollment in study
• Able and willing to provide consent

Exclusion criteria

• Patients who cannot tolerate laser therapy
• Patients who cannot wear protective eyewear
• Patients who are pregnant

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

21 participants in 1 patient group

Receiving treatment with both laser types

Experimental group

Description:

Participants will receive split-body treatment, receiving Nd:YAG laser treatment to an affected anatomical site (axilla, inframammary region, or groin) and Alexandrite laser to the contralateral side. The treatment side will be randomized and maintained through the study.

Treatment:

Device: Nd:YAG Laser

Device: Alexandrite Laser